AstraZeneca to Pay $110 Million to Settle Texas Drug Suits
- Texas said drugmaker pushed Seroquel for unapproved uses
- Deal also resolves separate claim over marketing of Crestor
AstraZeneca Plc's Seroquel
Photographer: JB Reed/Bloomberg
This article is for subscribers only.
AstraZeneca Plc agreed to pay $110 million to settle a Texas claim alleging that the company cheated the state’s Medicaid program by fraudulently marketing two medications, according to the state’s attorney general office.
The deal resolves the suits, which both date to 2013, at a fraction of the $5 billion the state sought. Texas claimed the drugmaker had targeted the state’s Medicaid program by urging doctors to prescribe its antipsychotic drug Seroquel for unapproved treatments, and that it had misrepresented Crestor, a cholesterol fighter, as superior to other statins.